Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy

JAMA Oncology 2026 Open access

Read full text
Authors: Ali J. Haidar, Angela Chen, Judy L. Chen, Saba Al-Hashimi, Reza S. Ghaffari, S. Fung, Jordyn Silverstein, Gottfried E. Konecny, Edmund Tsui
DOI: 10.1001/jamaoncol.2025.5763
Cited by: 4
References: 6

Abstract

This case series describes the management and outcomes of ocular toxic effects associated with mirvetuximab soravtansine therapy in female patients with folate receptor α–positive gynecologic malignant neoplasms.

Fields of Study & Subjects

Retinoids in leukemia and cellular processes Drug-Induced Ocular Toxicity Folate and B Vitamins Research

Publication details

Journal / source
JAMA Oncology
Publisher
American Medical Association (AMA)
Volume
12
Issue
3
Pages
317–317
Publication date
2 January 2026
Language
EN